Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 28, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,835,501

« Back to Dashboard

Which drugs does patent 8,835,501 protect, and when does it expire?


Patent 8,835,501 protects BELEODAQ and is included in one NDA.

This patent has thirty-five patent family members in twenty-six countries.

Summary for Patent: 8,835,501

Title:Pharmaceutical formulations of HDAC inhibitors
Abstract: This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
Inventor(s): Bastin; Richard J. (Waterford, IE), Hughes; Nicholas J. (Swindon, GB)
Assignee: TopoTarget UK Limited (Abingdon, Oxfordshire, GB)
Application Number:11/913,191
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Dosage form; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Spectrum Pharms
BELEODAQ
belinostat
POWDER;IV (INFUSION)206256-001Jul 3, 2014RXYesYes8,835,501► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,835,501

PCT Information
PCT FiledMay 11, 2006PCT Application Number:PCT/GB2006/001737
PCT Publication Date:November 16, 2006PCT Publication Number: WO2006/120456

International Patent Family for Patent: 8,835,501

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2606598► Subscribe
China101189003► Subscribe
China102579417► Subscribe
Cyprus1112498► Subscribe
Denmark1901729► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot